Claims for Patent: 10,058,564

Summary for Patent: 10,058,564

Title:	Methods of treating acne
Abstract:	A method of treating acne in a human in need thereof comprising administering systemically to said human a tetracycline compound in an amount that is effective to treat acne but has substantially no antibiotic activity, without administering a bisphosphonate compound.
Inventor(s):	Ashley; Robert A. (Newtown, PA)
Assignee:	Galderma Laboratories Inc. (Fort Worth, TX)
Application Number:	15/004,619
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,058,564
Patent Claims:	1. A method for treating papules and pustule of rosacea in a human in need thereof, the method comprising administering orally to said human doxycycline, or a pharmaceutically acceptable salt thereof, in an amount that is 5 mg to 40 mg total daily dose of doxycycline without administering a bisphosphonate compound. 2. The method according to claim 1, wherein said doxycycline, or a pharmaceutically acceptable salt thereof, is administered in an amount of 40 milligrams. 3. The method according to claim 2, wherein said doxycycline, or a pharmaceutically acceptable salt thereof, is administered by sustained release. 4. A method according to claim 3, wherein said doxycycline, or a pharmaceutically acceptable salt thereof, is administered once a day. 5. The method according to claim 1, wherein said doxycycline, or a pharmaceutically acceptable salt thereof, is administered in a dose of 20 mg twice a day. 6. The method according to claim 1, wherein said doxycycline, or a pharmaceutically acceptable salt thereof, is administered in an amount which provides a serum concentration in the range of about 0.1 to about 0.8 .mu.g/ml. 7. A method for treating papules and pustule of rosacea in a human in need thereof, the method comprising administering orally to said human doxycycline, or a pharmaceutically acceptable salt thereof, in an amount that (i) is 5 mg to 40 mg total daily dose of doxycycline and (ii) results in no reduction of skin microflora during a six-month treatment. 8. The method according to claim 7, wherein said doxycycline, or a pharmaceutically acceptable salt thereof, is administered in an amount of 40 milligrams. 9. The method according to claim 8, wherein said doxycycline, or a pharmaceutically acceptable salt thereof, is administered by sustained release. 10. A method according to claim 9, wherein said doxycycline is administered once a day. 11. The method according to claim 7, wherein said doxycycline, or a pharmaceutically acceptable salt thereof, is administered in a dose of 20 mg twice a day. 12. The method according to claim 7, wherein said doxycycline, or a pharmaceutically acceptable salt thereof, is administered in an amount which provides a serum concentration in the range of about 0.1 to about 0.8 .mu.g/ml. 13. The method of claim 1, wherein the method results in no reduction in skin microflora during a six month treatment. 14. The method of claim 1, wherein the doxycycline is doxycycline monohydrate. 15. The method of claim 1, wherein the doxycycline is doxycycline hyclate. 16. The method of claim 7, wherein the doxycycline is doxycycline monohydrate. 17. The method of claim 7, wherein the doxycycline is doxycycline hyclate.